|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||26.93 - 26.94|
|52 Week Range||19.96 - 27.35|
|PE Ratio (TTM)||41.26|
|Dividend & Yield||0.78 (2.90%)|
|1y Target Est||N/A|
In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Takeda Pharmaceutical Co., Ltd. Here are 5 ETFs with the largest exposure to TKPYY-US. Comparing the performance and risk of Takeda Pharmaceutical Co., Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.